Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management

Jafar Kafaie, MD, PhD;  Christopher Luzzio, MD


August 31, 2023

Although evidence regarding long-term management of CIDP is limited, the ProCID study is the largest randomized study to show that IVIg is effective as maintenance therapy in patients with CIDP. The study concluded that 1.0 g/kg IVIg is effective and well-tolerated as maintenance treatment following a 2.0 g/kg induction dose in patients with active CIDP, even in those successfully treated with corticosteroids. Further studies are needed to determine if a lower or higher maintenance dose might be beneficial in some patients.

Patients with very mild symptoms that do not significantly interfere with activities of daily living might not require treatment. However, therapy with corticosteroids or IVIg should be offered to patients with moderate or severe disability.

On the basis of very limited evidence, immunosuppressants may be considered in patients who become refractory to conventional treatment.

Learn more about medication in CIDP treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.